Tahsin Murat TURGAY, Müçteba Enes YAYLA, Murat TORGUTALP, İlyas Ercan OKATAN, Gülay KINIKLI, Didem ŞAHİN EROĞLU, Serdar SEZER, Ayşe Bahar KELEŞOĞLU DİNÇER, Emine Gözde AYDEMİR GÜLÖKSÜZ, Mehmet Levent YÜKSEL, Aşkın ATEŞ, Dilara DÖNMEZ GÜLER, Hasan Selim GÜLER, Zeynep Ceren KARAHAN

High mobility group box- 1 levels may be associated with disease activity of Behcet’s disease

Background/aim: High mobility group box- 1 (HMGB- 1) is a nuclear protein acting as a proinflammatory molecule. The serum HMGB- 1 levels were found elevated in chronic inflammatory diseases. In this cross-sectional study, serum HMGB- 1 levels in Behcet’s disease (BD) patients and healthy controls (HC) were studied. Also, its association with disease activity scores and clinical findings were evaluated. Materials and methods: Ninety BD patients and 50 age-sex matched HC were included in the study. Disease activity scores were assessed by Behcet Disease Current Activity Form (BDCAF) and Behcet Syndrome Activity Score (BSAS). Serum HMGB- 1 levels were measured using a commercial ELISA kit. A p value of < 0.05 was considered to be statistically significant. Results: Serum HMGB- 1 levels were significantly higher in BD than in HC (43.26 pg/mL and 16.73 pg/mL; p < 0.001, respectively). Serum HMGB- 1 levels were statistically significantly associated with presence of erythema nodosum (EN) and genital ulcers in the last one month prior to recruitment (p = 0.041 and p < 0.001, respectively). BDCAF and BSAS scores were positively correlated with serum HMGB- 1 level ( p = 0.03 and p = 0.02, respectively). Conclusion: HMGB - 1 may play a role in the development of BD. Also, due to its positive correlation with disease activity indices, it can be used as a novel disease activity parameter in BD. Key words: High mobility group box- 1, autoimmune diseases, Behcet’s disease, inflammation

PDF

___

1. Davatchi F. Behçet’s disease. International journal of rheumatic diseases 2018; 21 (12): 2057. doi: 10.1111/1756-185X.13465
2. de Chambrun MP, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet’s disease. Autoimmunity reviews 2012; 11 (10): 687-98. doi: 10.1016/j. autrev.2011.11.026
3. Lee S, Kwak MS, Kim S, Shin J-S. The role of high mobility group box 1 in innate immunity. Yonsei medical journal 2014; 55 (5): 1165-76. doi: 10.3349/ymj.2014.55.5.1165
4. Pilzweger C, Holdenrieder S. Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases. Diagnostics 2015; 5 (2): 219-53. doi: 10.3390/ diagnostics5020219
5. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer research 2002; 62 (16): 4805- 11. doi: Published August 2002
6. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. The Journal of biological chemistry 2004; 279 (9): 7370-7. doi: 10.1074/jbc.M306793200
7. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. American journal of physiology Cell physiology 2006; 290 (3): C917-24. doi: 10.1152/ ajpcell.00401.2005
8. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007; 110 (6): 1970-81. doi: 10.1182/blood-2006-09-044776
9. Kang R, Chen R, Zhang Q, Hou W, Wu S et al. HMGB1 in health and disease. Molecular aspects of medicine 2014; 40: 1-116. doi: 10.1016/j.mam.2014.05.001
10. Andersson U, Wang H, Palmblad K, Aveberger A-C, Bloom O et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. Journal of Experimental Medicine 2000; 192 (4): 565-70. doi: 10.1084/jem.192.4.565
11. Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N et al. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis & Rheumatism 2008; 58 (9): 2675-85. doi: 10.1002/ art.23729
12. Ma C-y, Jiao Y-l, Zhang J, Yang Q-r, Zhang Z-f et al. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatology international 2012; 32 (2): 395-402. doi: 10.1007/s00296-010-1636-6
13. Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis & Rheumatism 2004; 50 (5): 1586-94. doi: 10.1002/ art.20220
14. Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M, Hernández CJ, Riebeling-Navarro C et al. Etiopathogenesis of Behcet’s disease. Autoimmunity reviews 2010; 9 (4): 241-5. doi: 10.1016/j.autrev.2009.10.005
15. Ling E, Shubinsky G, Press J. Increased proportion of CD3+ CD4− CD8− double-negative T cells in peripheral blood of children with Behcet’s disease. Autoimmunity reviews 2007; 6 (4): 237-40. doi: 10.1016/j.autrev.2006.08.008
16. Emmi G, Bettiol A, Silvestri E, Di Scala G, Becatti M et al. Vascular Behçet’s syndrome: an update. Internal and Emergency Medicine 2019; 14 (5): 645-52. doi: 10.1007/ s11739-018-1991-y
17. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, RovereQuerini P. HMGB1: guiding immunity from within. Trends in immunology 2005; 26 (7): 381-7. doi: 10.1016/j.it.2005.04.009
18. Park JS, Arcaroli J, Yum H-K, Yang H, Wang H et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. American Journal of Physiology-Cell Physiology 2003; 284 (4): C870-C9. doi: 10.1152/ajpcell.00322.2002
19. ISGfBs D. Criteria for diagnosis of Behçet’s disease. International Study Group for Behcet’s Disease. Lancet 1990; 335: 1078-80.
20. Alpsoy E. Behcet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. The Journal of dermatology 2016; 43 (6): 620-32. doi: 10.1111/1346- 8138.13381
21. Boyvat A, Heper AO, Koçyiğit P, Erekul S, Gürgey E. Can specific vessel-based papulopustular lesions of Behçet’s disease be differentiated from nonspecific follicular-based lesions clinically? International journal of dermatology 2006; 45 (7): 814-8. doi: 10.1111/j.1365-4632.2006.02797.x
22. Türsen Ü. Behçet Hastalığında Aktivite Belirteçleri. Archives of the Turkish Dermatology & Venerology/Turkderm 2009; 43.
23. Yilmaz S, Simsek I, Cinar M, Erdem H, Kose O et al. Patientdriven assessment of disease activity in Behcet’s syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behcet’s Syndrome Activity Score. Clin Exp Rheumatol 2013; 31 (3 Suppl 77): 77-83.
24. de Souza AW, Félix Perazzio S, de França NR, Andrade LEC, Bijl M et al. High mobility group box 1 serum levels are increased in Behcet’s disease, but not associated with disease activity or disease manifestations. Rheumatology 2015; 54 (12): 2151-5. doi: 10.1093/rheumatology/kev202
25. Ha YJ, Park JS, Kang Mi, Lee SK, Park YB et al. Increased serum interleukin-32 levels in patients with Behçet’s disease. International journal of rheumatic diseases 2018; 21 (12): 2167-74. doi: 10.1111/1756-185X.13072
26. Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Molecular medicine 2014; 20 (1): 138-46. doi: 10.2119/molmed.2013.00164
27. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nature Reviews Rheumatology 2012; 8 (4): 195. doi: 10.1038/nrrheum.2011.222
28. Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 2010; 1799 (1-2): 141-8. doi: 10.1016/j.bbagrm.2009.11.003
29. Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, GallowitschPuerta M et al. Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Molecular medicine 2007; 13 (3-4): 210-5. doi: 10.2119/2006–00108.Goldstein
30. Dupire G, Nicaise C, Gangji V, Soyfoo MS. Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren’s syndrome. Scandinavian journal of rheumatology 2012; 41 (2): 120-3. doi: 10.3109/03009742.2011.633099
31. Wang C, Miao Y, Wu X, Huang Y, Sun M et al. Serum HMGB1 serves as a novel laboratory indicator reflecting disease activity and treatment response in ankylosing spondylitis patients. Journal of immunology research 2016; 2016. doi: 10.1155/2016/6537248
32. Taniguchi N, Kawahara KI, Yone K, Hashiguchi T, Yamakuchi M et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 2003; 48 (4): 971-81. doi: 10.1002/art.10859
33. Henes F, Chen Y, Bley T, Fabel M, Both M et al. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener’s). Annals of the rheumatic diseases 2011; 70 (11): 1926-9. doi: 10.1136/ard.2010.146456
34. Ahn JK, Cha H-S, Bae E-K, Lee J, Koh E-M. Extracellular highmobility group box 1 is increased in patients with Behcet’s disease with intestinal involvement. Journal of Korean medical science 2011; 26 (5): 697-700. doi: 10.3346/jkms.2011.26.5.697
35. De Martinis M, Sirufo MM, Ginaldi L. Osteoporosis: Current and emerging therapies targeted to immunological checkpoints. Current medicinal chemistry 2019. doi: 10.2174 /0929867326666190730113123
36. De Martinis M, Ginaldi L, Sirufo MM, Pioggia G, Calapai G et al. Alarmins in Osteoporosis, RAGE, IL-1, and IL-33 Pathways: A Literature Review. Medicina 2020; 56 (3): 138. doi: 10.3390/ medicina56030138
37. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte Integrins a novel pathway for inflammatory cell recruitment. The Journal of experimental medicine 2003; 198 (10): 1507-15. doi: 10.1084/jem.20030800
38. Demirkesen C, Tüzüner N, Mat C, Senocak M, Büyükbabani N et al. Clinicopathologic evaluation of nodular cutaneous lesions of Behçet syndrome. American journal of clinical pathology 2001; 116 (3): 341-6. doi: 10.1309/GCTH-0060-55K8-XCTT